Rahman A, Isemberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939
PubMed
CAS
Google Scholar
Jimenez S, Cervera R, Font J, Ingelmo M (2003) The epidemiology of systemic lupus erythematosus. Clin Rev Allergy Immunol 25:3–12
PubMed
Google Scholar
Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:277–287
Google Scholar
Pons-Estel GJ, Alarcón GS, Sconfield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39(4):257–268
PubMed
PubMed Central
Google Scholar
Cervera R, Khamashta MA, Font J, Sebastiani GD (1999) Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 78:167–175
CAS
Google Scholar
Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL (2010) Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10:3–7
PubMed
CAS
Google Scholar
Janko C, Schorn C, Grossmayer GE, Frey B, Herrmann M, Gaipl US, Munoz LE (2008) Inflammatory clearance of apoptotic remnants in systemic lupus erythematosus (SLE). Autoimmun Rev 8(1):9–12
PubMed
CAS
Google Scholar
Shrivastav M, Niewold TB (2013) Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 7(4):319
Google Scholar
Flesher DL, Sun X, Behrens TW, Graham RR, Criswell LA (2010) Recent advances in the genetics of systemic lupus erythematosus. Expert Rev Clin Immunol 6:461–479
PubMed
PubMed Central
Google Scholar
Crow MK (2008) Collaboration, genetic associations and lupus erythematosus. N Eng J Med 358:956–961
Bowness P, Davies KA, Norsworthy PJ, Athanassiou P, Taylor-Wiedeman J, Borysiewicz LK, Meyer PA, Walport MJ (1994) Hereditary C1q deficiency and systemic lupus erythematosus. QJM 87(8):455–464
PubMed
CAS
Google Scholar
Monticielo OA, Mucenic T, Machado Xavier R, Tavares Brenol JC, Bogo Chies JA (2008) The role of mannose-binding lectin in systemic lupus erythematosus. Clin Rheumatol 27:413–419
PubMed
Google Scholar
Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 100(5):2610–2615
PubMed
CAS
PubMed Central
Google Scholar
Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG et al (2004) Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 50(12):3958–3967
PubMed
CAS
Google Scholar
Rönnblom L, Alm GV, Eloranta ML (2011) The type I interferon system in the development of lupus. Semin Immunol 23:113–121
PubMed
Google Scholar
Deng Y, Tsao BP (2010) Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat Rev Rheumatol 6(12):683–92.10
Zhao S, Long H, Qiaanjin L (2010) Epigenetic perspectives in systemic lupus erythematosus: pathogenesis, biomarkers and therapeutic potentials. Clin Rev Allergy Immunol 39:3–9
Wen ZK, Xu W, Xu L, Cao QH, Wang Y, Chu YW, Xiong SD (2007) DNA hypomethylation is crucial for apoptotic DNA to induce systemic lupus erythematosus-like autoimmune disease in SLE-non-susceptible mice. Rheumatology (Oxford) 46:1796–1803
CAS
Google Scholar
Ballestar E, Esteller M, Richardson BC (2006) The epigenetic face of systemic lupus erythematosus. J Immunol 176:7143–7147
PubMed
CAS
Google Scholar
Rigby RJ, Vinuesa CG (2008) Silencing SLE: the power and promise of small noncoding RNAs. Curr Opin Rheumatol 20:526–531
PubMed
CAS
Google Scholar
Stagakis E, Bertsias G, Verginis P, Nakou M, Hatziapostolou M, Kritikos H, Iliopoulos D, Boumpas DT (2011) Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: mir-21 regulates aberrant T-cells response trough the regulation of PDCD4 expression. Ann Rheum Dis 70:1496–1506
PubMed
CAS
Google Scholar
Weckerle CE, Niewold TB (201) The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clin Rev Allergy Immunol 40:42–49
González DA, Díaz BB, Rodríguez Pérez Mdel C, Hernández AG, Chico BN, De León AC (2010) Sex hormones and autoimmunity. Immunol Lett 133:6–13
PubMed
Google Scholar
Kassi E, Moutsatsou P (2010) Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2010:317–452
Wang J, Nuite M, McAlindon TE (2010) Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus 19(6):734–740
PubMed
CAS
PubMed Central
Google Scholar
Shoenfeld Y, Tincani A, Gershwin ME (2012) Sex gender and autoimmunity. J Autoimmun 38(2–3):J71–J73
PubMed
CAS
Google Scholar
Hudson CA, Cao L, Kasten-Jolly J, Kirkwood JN, Lawrence DA (2003) Susceptibility of lupus-prone NZM mouse strains to lead exacerbation of systemic lupus erythematosus symptoms. J Toxicol Environ Health A 66(10):895–918
PubMed
CAS
Google Scholar
Hughes GC, Clark EA (2007) Regulation of dendritic cells by female sex steroids: relevance to immunity and autoimmunity. Autoimmunity 40(6):470–481
PubMed
CAS
Google Scholar
Tayel SS, Helmy AA, Ahmed R, Esmat G, Hamdi N, Abdelaziz AI (2013) Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Arch Virol 158(8):1755–1764
PubMed
CAS
Google Scholar
Shelly S, Boaz M, Orbach H (2012) Prolactin and autoimmunity. Autoimmun Rev 11(6–7):A465–A467
PubMed
CAS
Google Scholar
Doria A, Canova M, Tonon M, Zen M, Rampudda E, Bassi N, Atzeni F, Zampieri S, Ghirardello A (2008) Infections as trigger and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28
PubMed
CAS
Google Scholar
Zandman-Goddard G, Schoenfeld Y (2005) Infections and SLE. Autoimmunity 38:473–485
PubMed
CAS
Google Scholar
Poole BD, Scofield RH, Harley JB, James JA (2006) Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity 39:63–70
PubMed
CAS
Google Scholar
James J, Harley JB, Scofield RH (2006) Role of Epstein–Barr virus in systemic lupus erythematosus. Curr Opin Rheumatol 18:462–467
PubMed
Google Scholar
Werth VP (2007) Cutaneous lupus: insight into pathogenesis and disease classification. Bull NYU Hosp Jt Dis 65:200–204
PubMed
Google Scholar
Kuhn A, Wenzel J, Weyd H (2014) Photosensitivity, apoptosis, and cytokines in the pathogenesis of lupus erythematosus: a critical review. Clin Rev Allergy Immunol. (Epub ahead of print)
Chang C, Gershwin ME (2010) Drugs and autoimmunity—a contemporary review and mechanistic approach. J Autoimmun 34(3):J266–J275
PubMed
CAS
Google Scholar
Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289
PubMed
Google Scholar
Ravichandran KS, Lorenz U (2007) Engulfment of apoptotic cells: signals for a good meal. Nat Rev Immunol 7:964–974
PubMed
CAS
Google Scholar
Mevorach D, Trahtemberg U, Krispin A, Attalah M, Zazoun J, Tabib A, Grau A, Verbovetski-Reiner I (2010) What do we mean when we write “senescence,” “apoptosis,” “necrosis,” or “clearance of dying cells”? Ann N Y Acad Sci 1209:1–9
Poon IK, Lucas CD, Rossi AG, Ravichandran KS (2014) Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 14(3):166–180
PubMed
CAS
PubMed Central
Google Scholar
Pisetsky DS, Erlandsson-Harris H, Andersson U (2008) High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 10:209
PubMed
PubMed Central
Google Scholar
Ma CY, Jiao YL, Zhang J, Yang QR, Zhang ZF, Shen YJ, Chen ZJ, Zhao YR (2012) Elevated plasma level of HMGB1 is associated with disease activity and combined alterations with IFN-alpha and TNF-alpha in systemic lupus erythematosus. Rheumatol Int 32:395–402
PubMed
CAS
Google Scholar
Hurst J, Von Landenberg P (2008) Toll-like receptors and autoimmunity. Autoimmun Rev 7:204–208
PubMed
CAS
Google Scholar
Marshak-Rothstein A (2006) Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 6:823–835
PubMed
CAS
Google Scholar
Theofilopoulos AN (2012) TLRs and IFNs: critical pieces of the autoimmunity puzzle. J Clin Invest 122(10):3464–3466
Pisetsky DS, Ullal AJ (2010) The blood nucleome in the pathogenesis of SLE. Autoimmun Rev 10:35–37
PubMed
CAS
PubMed Central
Google Scholar
Kontaki E, Boumpas DT (2010) Innate immunity in systemic lupus erythematosus: sensing endogenous nucleic acids. J Autoimmun 35:206–211
PubMed
CAS
Google Scholar
Fransen JH, van der Vlag J, Ruben J, Adema GJ, Berden JH, Hilbrands LB (2010) The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 12:207
PubMed
PubMed Central
Google Scholar
Crispín JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, Tsokos GC (2010) Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 16:47–57
PubMed
PubMed Central
Google Scholar
Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK (2005) Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 52(5):1491–1503
PubMed
CAS
Google Scholar
Nzeusseu Toukap A, Galant C, Theate I, Maudoux AL, Lories RJ, Houssiau FA, Lauwerys BR (2007) Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 56(5):1579–1588
Liu Z, Davidson A (2013) IFNα inducible models of murine SLE. Front Immunol 2(4):306
Google Scholar
Koss MN, Stohl W, Kovats S, Jacob CO (2009) Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 183(9):6021–6029
PubMed
PubMed Central
Google Scholar
Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S (2005) IFN-α induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J. Immunol 174:2499–2506
Google Scholar
Fairhurst AM et al (2008) Systemic IFN-α drives kidney nephritis in B6.SLE123 mice. Eur J Immunol 38:1948–1960
PubMed
CAS
PubMed Central
Google Scholar
Wilson LE, Widman D, Dikman SH, Gorevic PD (2002) Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32(3):163–173
PubMed
Google Scholar
Rönnblom LE, Alm GV, Öberg KE (1990) Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumor. J Intern Med 227:207–210
PubMed
Google Scholar
Hargraves MM, Richmond H, Morton R (1948) Presentation of two bone marrow elements; the tart cell and the LE cell. Proc Staff Meet Mayo Clin 23:25–28
PubMed
CAS
Google Scholar
Branzk N, Papayannopoulos V (2013) Molecular mechanisms regulating NETosis in infection and disease. Semin Immunopathol 35(4):513–530
PubMed
CAS
PubMed Central
Google Scholar
Knight JS, Kaplan MJ (2012) Lupus neutrophils: ‘NET’ gain in understanding lupus pathogenesis. Curr Opin Rheumatol 24:441–450
PubMed
CAS
Google Scholar
Garcia-Romo GS et al (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3:73ra20
Hakkim A, Furnrohr BG, Amann K et al (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 107:9813–9818
PubMed
CAS
PubMed Central
Google Scholar
Scheinecker C, Bonelli M, Smolen JS (2010) Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. J Autoimmun 35:269–275
PubMed
CAS
Google Scholar
Peng SL (2009) Altered T and B lymphocyte signaling pathways in lupus. Autoimmun Rev 8:179–183
PubMed
CAS
Google Scholar
Truchetet ME, Mossalayi MD, Boniface K (2013) IL-17 in the rheumatologist’s line of sight. Biomed Res Int 2013:295132
PubMed
PubMed Central
Google Scholar
Nalbandian A, Crispín JC, Tsokos GC (2009) Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol 157(2):209–215
PubMed
CAS
PubMed Central
Google Scholar
Chen DY, Chen YM, Wen MC, Hsieh TY, Hung WT, Lan JL (2012) The potential role of Th17 cells and Th17-related cytokines in the pathogenesis of lupus nephritis. Lupus 21(13):1385–1396
PubMed
Google Scholar
Ohl K, Tenbrock K (2011) Inflammatory cytokines in systemic lupus erythematosus. J Biomed Biotechnol 2011, Art id 432595
Savino MT, Ulivieri C, Emmi G, Prisco D, De Falco G, Ortensi B, Beccastrini E, Emmi L, Pelicci G, D’Elios MM, Baldari CT (2013) The Shc family protein adaptor, Rai, acts as a negative regulator of Th17 and Th1 cell development. J Leukoc Biol 93(4):549–559
PubMed
CAS
Google Scholar
Valencia X, Yarboro C, Illei G, Lipsky PE (2007) Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178:2579–2588
PubMed
CAS
Google Scholar
Bonelli M et al (2008) Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 20:861–868
PubMed
CAS
Google Scholar
Yu A, Zhu L, Altman NH, Malek TR (2009) A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells. Immunity 30:204–217
PubMed
CAS
PubMed Central
Google Scholar
Wan S, Xia C, Morel L (2007) IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+ CD25+ T cell regulatory functions. J. Immunol 178:271–279
PubMed
CAS
Google Scholar
Chen X, Oppenheim JJ (2014) Th17 cells and Tregs: unlikely allies. J Leukoc Biol
Gerli R, Nocentini G, Alunno A, Bocci EB, Bianchini R, Bistoni O, Riccardi C (2009) Identification of regulatory T cells in systemic lupus erythematosus. Autoimmun Rev 8:426–430
PubMed
CAS
Google Scholar
Kuhn A, Beissert S, Krammer PH (2009) CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 301:71–81
PubMed
Google Scholar
Jenks SA, Sanz I (2009) Altered B cell receptor signaling in human systemic lupus erythematosus. Autoimmun Rev 8(3):209–213
PubMed
CAS
PubMed Central
Google Scholar
Grammer AC, Lipsky PE (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5:S22–S27
PubMed
PubMed Central
Google Scholar
Liossis SN, Kovacs B, Dennis G, Kammer GM, Tsokos GC (1996) B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 98(11):2549–2557
PubMed
CAS
PubMed Central
Google Scholar
Liu K, Mohan C (2009) Altered B-cell signaling in lupus. Autoimmun Rev 8:214–218
PubMed
Google Scholar
Lopes-Carvalho T, Kearney JF (2005) Marginal zone B cell physiology and disease. Curr Dir Autoimmun 8:91–123
PubMed
CAS
Google Scholar
Martinez-Gamboa L, Mei H, Loddenkemper C, Ballmer B, Hansen A, Lipsky PE, Emmerich F, Radbruch A, Salama A, Dörner T (2009) Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clin Immunol 130(2):199–212
PubMed
CAS
Google Scholar
Sang A, Zheng YY, Morel L (2013) Contributions of B cells to lupus pathogenesis. Mol Immunol [Epub ahead of print]
Wither JE, Roy V, Brennan LA (2000) Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB × NZW)F(1) mice. Clin Immunol 94(1):51–63
PubMed
CAS
Google Scholar
Wang JH, Wu Q, Yang P, Li H, Li J, Mountz JD, Hsu HC (2011) Type I interferon-dependent CD86(high) marginal zone precursor B cells are potent T cell costimulators in mice. Arthritis Rheum 63(4):1054–1064
PubMed
CAS
PubMed Central
Google Scholar
Weller S, Braun MC, Tan BK, Rosenwald A, Cordier C, Conley ME, Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Steiniger B, Staudt LM, Casanova JL, Reynaud CA, Weill JC (2004) Human blood IgM “memory” B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire. Blood 104(12):3647–3654
PubMed
CAS
PubMed Central
Google Scholar
Anolik JH et al (2007) Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 56:3044–3056
PubMed
CAS
Google Scholar
Goode I, Xu H, Ildstad ST (2014) Regulatory B cells: the new “it” cell. Transplant Proc 46(1):3–8
Iwata Y, Matsushita T, Horikawa M et al (2011) Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 117:530–541
PubMed
CAS
PubMed Central
Google Scholar
Matsushita T, Horikawa M, Iwata Y, Tedder TF (2010) Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. J Immunol 185:2240–2252
PubMed
CAS
PubMed Central
Google Scholar
Carter NA, Rosser EC, Mauri C (2012) Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther 14(1):R32
PubMed
CAS
PubMed Central
Google Scholar
Yang X, Yang J, Chu Y, Xue Y, Xuan D, Zheng S, Zou H (2014) T follicular helper cells and regulatory B cells dynamics in systemic lupus erythematosus. PLoS One 9(2):e88441
PubMed
PubMed Central
Google Scholar
Sanz I, Lee FE (2010) B cells as therapeutic targets in SLE. Nat Rev Rheumatol 6(6):326–337
PubMed
CAS
PubMed Central
Google Scholar
Manjarrez-Orduño N, Quách TD, Sanz I (2009) B cells and immunological tolerance. J Invest Dermatol 129(2):278–288
PubMed
Google Scholar
Jacob N, Stohl W (2011) Cytokine disturbances in systemic lupus erythematosus. Arthritis Res Ther 13:228
PubMed
CAS
PubMed Central
Google Scholar
Ding H, Wang L, Wu X, Yan J, He Y, Ni B et al (2010) Blockade of B-cell-activating factor suppresses lupus-like syndrome in autoimmune BXSB mice. J Cell Mol Med 14:1717–1725
PubMed
CAS
PubMed Central
Google Scholar
Chu VT, Enghard P, Schürer S, Steinhauser G, Rudolph B, Riemekasten G (2009) Berek C Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60:2083–2093
PubMed
CAS
Google Scholar
Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F (2013) The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev 24(3):203–215
PubMed
CAS
Google Scholar
Yildirim-Toruner C, Diamond B (2011) Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol 127:303–312
Vincent FB, Morand EF, Schneider P, Mackay F (2014) The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10(6):365–373
Dörner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5(8):433–441
PubMed
Google Scholar
Mok MY (2010) The immunological basis of B-cell therapy in systemic lupus erythematosus. Int J Rheum Dis 13:3–11
PubMed
Google Scholar
Silverman GJ (2006) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54(8):2356–2367
PubMed
CAS
Google Scholar
García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Galarza-Maldonado C, Sandoval-Cruz M, Zamudio-Huerta L, López-Colombo A, Cervera R (2009) Use of rituximab in patients with systemic lupus erythematosus. Autoimmun Rev 8:343–348
PubMed
Google Scholar
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG (2010) Efficacy and safety of Rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222–233
PubMed
CAS
PubMed Central
Google Scholar
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G, LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215–1226
PubMed
CAS
Google Scholar
Isenberg D (2012) Rituximab-it was the best of times, it was the worst of times. Autoimmun Rev 11(11):790–791
PubMed
CAS
Google Scholar
Reddy V, Jayne D, Close D, Isenberg D (2013) B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 15(Suppl 1):S2
PubMed
PubMed Central
Google Scholar
Wallace DJ, Kalunian K, Petri MA, Strand V, Houssiau FA, Pike M, Kilgallen B, Bongardt S, Barry A, Kelley L, Gordon C (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73(1):183–190
PubMed
CAS
PubMed Central
Google Scholar
Stohl W, Scholz JL, Cancro MP (2011) Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside. Curr Opin Rheumatol 23:305–310
PubMed
PubMed Central
Google Scholar
Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61(9):1168–1178
PubMed
CAS
PubMed Central
Google Scholar
Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721–731
PubMed
CAS
Google Scholar
Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918–3930
PubMed
CAS
Google Scholar
Ginzler EM et al (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41(2):300–309
Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14:R33
PubMed
CAS
PubMed Central
Google Scholar
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168:2046–2053
PubMed
CAS
Google Scholar
Merrill JT (2013) Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol 148(3):369–375
PubMed
CAS
Google Scholar
Kalunian KC, Davis JC Jr, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258
PubMed
CAS
Google Scholar
Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A, BG9588 Lupus Nephritis Trial Group (2003) A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 48(3):719–727
PubMed
CAS
Google Scholar
Sidiropoulos PI, Boumpas DT (2004) Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5):391–397
PubMed
CAS
Google Scholar
Wang X, Huang W, Mihara M, Sinha J, Davidson A (2002) Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 168(4):2046–2053
PubMed
CAS
Google Scholar
Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D’Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087
PubMed
CAS
Google Scholar
Mok CC (2012) Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther 12(12):1559–1561
PubMed
CAS
Google Scholar
Van Vollenhoven RF, Parodis I, Levitsky A (2013) Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 27(3):341–349
PubMed
Google Scholar
Aderka D, Wysenbeek A, Engelmann H, Cope AP, Brennan F, Molad Y, Hornik V, Levo Y, Maini RN, Feldmann M et al (1993) Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupuserythematosus. Arthritis Rheum 36(8):1111–1120
PubMed
CAS
Google Scholar
Postal M, Appenzeller S (2011) The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 56(3):537–543
PubMed
CAS
Google Scholar
Aringer M, Smolen JS (2012) Therapeutic blockade of TNF in patients with SLE-promising or crazy? Autoimmun Rev 11(5):321–325
PubMed
CAS
Google Scholar
Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50(10):3161–3169
PubMed
CAS
Google Scholar
Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA (2008) Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 22(5):847–861
PubMed
CAS
Google Scholar
Soforo E, Baumgartner M, Francis L, Allam F, Phillips PE, Perl A (2010) Induction of systemic lupus erythematosus with tumor necrosis factor blockers. J Rheumatol 37(1):204–205
PubMed
CAS
Google Scholar
Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR (1991) Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 147(1):117–123
PubMed
CAS
Google Scholar
Woodrick RS, Ruderman EM (2011) Interleukin 6 inhibition—RA and beyond. Bull NYU Hosp Jt Dis 69(3):225–229
PubMed
Google Scholar
Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552
PubMed
CAS
PubMed Central
Google Scholar
Kamata Y, Minota S (2012) Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep 21:2012
Google Scholar
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B (2013) Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65(10):2661–2671
PubMed
CAS
Google Scholar
Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B (2009) Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 60(6):1785–1796
PubMed
CAS
Google Scholar
McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676
PubMed
CAS
Google Scholar
Lichtman AI, Helfgott SM, Kriegel MA (2012) Emerging therapies for systemic lupus erythematosus—focus on targeting interferon-alpha. Clin Immunol 143:210–221
PubMed
CAS
PubMed Central
Google Scholar
Lauwerys BR, Ducreux J, Houssiau FA (2013) Type I interferon blockade in systemic lupus erythematosus: where do we stand? Rheumatology (Oxford) 53(8):1369–1376